EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis

Rahul S Dalal, Karen M Kwaning, Mia E Silvestri, Alexander D Carlin, Heidy J Cabral, Jessica R Allegretti

Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3157-3159

DOI: 10.1016/j.cgh.2026.01.032 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Rahul S Dalal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massac…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring. Die Arbeit nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape of moderate-to-severe ulcerative colitis (UC) has diversified with the incorporation of Janus kinase inhibitors (JAKis) and interleukin (IL) antagonists. Upadacitinib, a selective JAK-1 inhibitor, and risankizumab, an inhibitor of the p19 subunit of IL-23, have demonstrated efficacy for UC in randomized trials.1,2 However, head-to-head comparisons of these therapies are needed to guide treatment positioning. We therefore compared the effectiveness and safety of upadacitinib and risankizumab in a real-world UC cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHeterocyclic Compounds, 3-RingHumansTreatment OutcomeFemaleMaleAdultDrug-Related Side Effects and Adverse Reactions

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: rsdalal@bwh.harvard.edu.
  • Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Dalal, R. S., Kwaning, K. M., Silvestri, M. E., Carlin, A. D., Cabral, H. J., & Allegretti, J. R. (2026). Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 24(11), 3157-3159. https://doi.org/10.1016/j.cgh.2026.01.032

Vancouver

Dalal RS, Kwaning KM, Silvestri ME, Carlin AD, Cabral HJ, Allegretti JR. Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2026;24(11):3157-3159. doi:10.1016/j.cgh.2026.01.032

BibTeX
@article{Dalal2026,
  author = {Dalal, Rahul S and Kwaning, Karen M and Silvestri, Mia E and Carlin, Alexander D and Cabral, Heidy J and Allegretti, Jessica R},
  title = {Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {3157--3159},
  doi = {10.1016/j.cgh.2026.01.032}
}
Kostenlos starten →